Bromocriptine — Discount Pricing

Other medications in Diabetes & Endocrine

• Desmopressin Oral
• Hydrocortisone Oral
• Lanreotide
• Pegvisomant

What Bromocriptine is approved for (FDA label)

Bromocriptine mesylate is an ergot derivative indicated for the treatment of: Hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility, or hypogonadism in adults ( 1.1 ) Prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older ( 1.2 ). Acromegaly in adults ( 1.3 ). Signs and symptoms of idiopathic Parkinson's disease or postencephalitic parkinsonism in adults ( 1.4 ). Limitations of Use Avoid use of bromocriptine mesylate capsule for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions ( 1.1 , 5.4 ) 1.1 Hyperprolactinemia-Associated Dysfunction Bromocriptine mesylate capsules are indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility or hypogonadism in adults.

Source: Read the full FDA label on DailyMed. Label effective date: July 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Bromocriptine (FDA label)

Bromocriptine Mesylate Capsules USP, 5 mg are white to off-white powder filled in size "3" empty Cellulose capsules with tan colored cap printed with "ZA 17" in black ink and white colored body printed with "5 mg" in black ink. Capsules: 5 mg of bromocriptine mesylate ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d69003ee-0b6f-47a9-834e-ba59c02f566c. SPL document ID: 98e43e82-81ff-465b-a27d-f620b182705c. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Bromocriptine (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiac Valvulopathy and Pericardial Fibrosis [see Warnings and Precautions ( 5.1 )] Pleural, Pulmonary, and Retroperitoneal Fibrosis [see Warnings and Precautions ( 5.2 )] Hypotension/Orthostatic Hypotension [see Warnings and Precautions ( 5.3 )] Risks with Use of bromocriptine mesylate for Postpartum Lactation Inhibition or Suppression [see Warnings and Precautions ( 5.4 )] Impulse Control Disorders and Compulsive Behaviors [see Warnings and Precautions ( 5.5 )] Falling Asleep During Activities of Daily Living [see Warnings and Precautions ( 5.6 )] Visual Impairment in Patients with Prolactin-secreting Adenomas [see Warnings and Precautions ( 5.7 )] Exacerbation of Psychosis in Patients with Severe Psychotic Disorders [see Warnings and Precautions ( 5.8 )] Risks in Patients with Hereditary Problems of Galactose Intolerance, Severe Lactase Deficiency, or Glucose-Galactose Malabsorption [see Warnings and Precautions ( 5.9 )] Additional Clinically Significant Adverse Reactions and Risks in Patients with Acromegaly [see Warnings and Precautions ( 5.10 )] Additional Clinically Significant Adverse Reactions and Risks in Patients with Idiopathic Parkinson's Disease or Postencephalitic Parkinsonism [see Warnings and Precautions ( 5.11 )] Most common adverse reactions: ( 6.1 ) Hyperprolactinemia-Associated Dysfunctions and Prolactin-secreting Adenomas: (incidence >5%) are nausea, headache, dizziness, fatigue, lightheadedness, and vomiting.

Source: FDA prescribing information (DailyMed). Set ID: d69003ee-0b6f-47a9-834e-ba59c02f566c. SPL document ID: 98e43e82-81ff-465b-a27d-f620b182705c. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Bromocriptine (FDA label)

Bromocriptine mesylate capsules are contraindicated in patients with: History of cardiac valvular disorders or a history of pericardial fibrosis [see Warnings and Precautions ( 5.1 )]. History of pleural, pulmonary, or retroperitoneal fibrotic disorders [see Warnings and Precautions ( 5.2 )]. Uncontrolled hypertension [see Warnings and Precautions ( 5.3 )]. Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate capsules or sensitivity to other ergot alkaloids. Bromocriptine mesylate capsules is contraindicated in patients with: History of cardiac valvular disorders or a history of pericardial fibrosis ( 4 , 5.1 ). History of pleural, pulmonary, or retroperitoneal fibrotic disorders ( 4 , 5.2 ) Uncontrolled hypertension ( 4 , 5.3 ) Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate capsules or sensitivity to other ergot alkaloids ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: d69003ee-0b6f-47a9-834e-ba59c02f566c. SPL document ID: 98e43e82-81ff-465b-a27d-f620b182705c. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Bromocriptine (FDA label)

Cardiac Valvulopathy and Pericardial Fibrosis: During bromocriptine mesylate treatment, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated and monitor for chest pain and signs and symptoms of heart failure (if heart failure occurs, exclude valvular fibrosis and pericarditis). Consider additional clinical and diagnostic monitoring at baseline and as necessary during bromocriptine mesylate treatment. Use bromocriptine mesylate in patients treated with other drugs associated with valvulopathy is not recommended. Discontinue bromocriptine mesylate if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis. ( 5.1 ) Pleural, Pulmonary and Retroperitoneal Fibrosis: During bromocriptine mesylate treatment monitor for signs and symptoms of progressive fibrosis, (e.g., pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular obstruction). Consider clinical and diagnostic monitoring for pleural, pulmonary, and retroperitoneal fibrosis at baseline and as necessary during bromocriptine mesylate treatment.

Source: FDA prescribing information (DailyMed). Set ID: d69003ee-0b6f-47a9-834e-ba59c02f566c. SPL document ID: 98e43e82-81ff-465b-a27d-f620b182705c. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Bromocriptine (FDA label)

Alcohol Alcohol may potentiate bromocriptine mesylate -associated adverse reactions. Dopamine Antagonists The concomitant use of bromocriptine mesylate with dopamine antagonists resulted in a decreased efficacy of bromocriptine mesylate. Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of bromocriptine mesylate with strong CYP3A4 inhibitors. Follow the recommended bromocriptine mesylate dosage modifications during concomitant use with moderate CYP3A4 inhibitors [see Dosage and Administration ( 2.7 )]. Bromocriptine is a substrate of CYP3A4 [see Clinical Pharmacology ( 12.3 )] . Concomitant use with strong and moderate CYP3A4 inhibitors increases bromocriptine exposure [see Clinical Pharmacology ( 12.3 )], which may increase the risk of bromocriptine mesylate-associated adverse reactions. Ergot Alkaloids Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended. If use is unavoidable, dosage reduction may be necessary in those cases where high dosages of bromocriptine mesylate are being used (such as patients with Parkinson's disease).

Source: FDA prescribing information (DailyMed). Set ID: d69003ee-0b6f-47a9-834e-ba59c02f566c. SPL document ID: 98e43e82-81ff-465b-a27d-f620b182705c. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.